CAS 877130-28-4

Filibuvir

Description:

Filibuvir is an antiviral compound primarily investigated for its potential use in the treatment of hepatitis C virus (HCV) infections. It belongs to the class of non-nucleoside polymerase inhibitors, which function by interfering with the viral RNA polymerase, thereby inhibiting viral replication. The chemical structure of Filibuvir includes a unique arrangement of functional groups that contribute to its activity and selectivity against HCV. It has demonstrated efficacy in various preclinical and clinical studies, showing promise in combination therapies to enhance treatment outcomes. Filibuvir's pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, are critical for its therapeutic application, influencing dosing regimens and potential side effects. As with many antiviral agents, resistance development is a concern, necessitating ongoing research to optimize its use in clinical settings. Overall, Filibuvir represents a significant advancement in the ongoing efforts to combat hepatitis C, particularly in the context of combination therapies aimed at achieving sustained virologic response in patients.

Formula: C₂₉H₃₇N₅O₃

InChI: InChI=1S/C29H37N5O3/c1-5-22-14-20(15-23(6-2)31-22)11-12-29(21-9-7-8-10-21)17-25(35)24(27(36)37-29)16-26-32-28-30-18(3)13-19(4)34(28)33-26/h13-15,21,35H,5-12,16-17H2,1-4H3/t29-/m1/s1

InChI key: InChIKey=SLVAPEZTBDBAPI-GDLZYMKVSA-N

SMILES: C(CC=1C=C(CC)N=C(CC)C1)[C@@]2(CC(O)=C(CC3=NN4C(=N3)N=C(C)C=C4C)C(=O)O2)C5CCCC5

Synonyms:

• (6R)-6-Cyclopentyl-6-[2-(2,6-diethyl-4-pyridinyl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-5,6-dihydro-4-hydroxy-2H-pyran-2-one
• PF 00868554
• Filibuvir
• 2H-Pyran-2-one, 6-cyclopentyl-6-[2-(2,6-diethyl-4-pyridinyl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-5,6-dihydro-4-hydroxy-, (6R)-
• (R)-6-Cyclopentyl-6-[2-(2,6-diethylpyridin-4-yl)ethyl]-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one

Filibuvir

CAS: 877130-28-4

Filibuvir

Purity: ≥98%

Molecular weight: 503.64g/mol

Ref: 54-BUP16302

(6R)-6-Cyclopentyl-6-[2-(2,6-diethyl-4-pyridinyl)ethyl]-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-5,6-dihydro-4-h ydroxy-2H-pyran-2-one

CAS: 877130-28-4

Fidovirsen is a nucleoside analogue that is an inhibitor of the NS3 protease of hepatitis C virus (HCV). Fidovirsen binds to the active site of the NS3 protease and prevents cleavage at the NS3/4A interface, thus inhibiting viral replication. It has been shown to be effective in clinical studies involving human liver samples. Fidovirsen has also been shown to have antiviral activity against other RNA viruses, including HIV-1 and influenza A virus. Fidovirsen has a low toxicity profile and does not exhibit cross-resistance with other antiviral drugs. The drug is being developed as a potential therapy for chronic HCV infection.

Formula: C₂₉H₃₇N₅O₃

Purity: Min. 95%

Molecular weight: 503.64 g/mol

Ref: 3D-FC152905

Filibuvir

CAS: 877130-28-4

Filibuvir (PF-00868554) inhibits HCV polymerase genotypes 1a/1b, EC50s 59 nM.

Formula: C₂₉H₃₇N₅O₃

Purity: 99.28% - >99.99%

Color and Shape: Solid

Molecular weight: 503.64

Ref: TM-T15282